Australia's most trusted
source of pharma news
Posted 22 May 2024 PM
The Federal Government will ban "dangerous" compounded replicas of blockbuster weight loss drugs Novo Nordisk's Ozempic and Lilly's Mounjaro from October on the advice of the TGA, insisting it will save lives.
Under new regulations, pharmacists and other healthcare practitioners will no longer be allowed to compound GLP-1 RAs. It follows a growing number of reports of harm to patients using the fake products, including one hospitalisation in Australia due to a serious adverse event.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.